Open AccessPotential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study
Author(s) -
Emmanuelle Scala,
Christiane Gerschheimer,
Francisco Gómez,
Lorenzo Alberio,
Carlo Marcucci
Publication year - 2020
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000004700
Subject(s) - cangrelor , medicine , heparin , platelet factor 4 , anticoagulant , interquartile range , platelet poor plasma , pharmacology , platelet rich plasma , platelet activation , hemostasis , anesthesia , platelet , p2y12 , platelet aggregation
Heparin-induced thrombocytopenia (HIT) can put cardiac surgery patients at a high risk of lethal complications. If anti-PF4/heparin antibodies (anti-PF4/Hep Abs) are present, 2 strategies exist to prevent intraoperative aggregation during bypass surgery: first, using an alternative anticoagulant, and second, using heparin combined with an antiaggregant. The new P2Y12 inhibitor, cangrelor, could be an attractive candidate for the latter strategy; several authors have reported its successful use. The present in vitro study evaluated cangrelor's ability to inhibit heparin-induced platelet aggregation in the presence of anti-PF4/Hep Abs.